Scientists said the drug trial of the treatment for melanoma could be the beginning of a transformation in care.
"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins ...
ROCHESTER, N.Y. (WROC)-Health officials say a potential new weapon in the fight against melanoma is showing promising results. Moderna and Merck say their new personalized mRNA treatment helped ...
Explore promising oncology stocks after Moderna/Merck melanoma data: analysts cite IOVA, NUVB, COGT, OPK, LEGN, PFE, ABT.
The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate ...
The companies said their vaccine helped prevent the return and spread of melanoma in a trial that involved more than 1,000 ...
Whether you're eligible for the mRNA shot or the standard one, health officials encouraged New Yorkers to get vaccinated amid ...
The next generation of mRNA medicines – including vaccines fighting against infectious disease, cancer and autoimmune ...
ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer ...
Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a ...
A new personalized vaccine given in combination with another drug has reduced the chances of a type of skin cancer returning ...
Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results